经导管动脉栓塞术治疗肝包膜下血肿
本研究纳入34例肝包膜下血肿患者,病因包括肝肿瘤破裂、外伤、医源性并发症及自发性出血,评估经导管动脉栓塞术(TAE)的技术成功率和临床成功率。结果显示技术成功率94.1%,临床成功率73.5%,6例患者TAE后一个月内死亡,3例重复TAE,4例手术清除血肿止血,1例肝衰竭;根据血管造影有无逆部门静脉血流分组比较,两组技术成功率、临床成功率及TAE后血检结果差异均无统计学意义。结论认为TAE治疗肝包膜下血肿有效且安全,逆部门静脉血流不影响TAE成功率及肝损伤。
要点
- TAE治疗肝包膜下血肿技术成功率94.1%,临床成功率73.5%。
- 血管造影可见逆部门静脉血流者18例,其TAE成功率及肝损伤与无逆流者无差异。
- TAE后一个月内死亡6例,需重复TAE 3例,手术清除血肿止血4例,肝衰竭1例。
核心结论
- TAE是治疗肝包膜下血肿有效且安全的方法,技术成功率和临床成功率分别为94.1%和73.5%。
- 血管造影有无逆部门静脉血流不影响TAE的技术成功率、临床成功率及TAE后血检结果。
研究设计与样本
- 回顾性研究,纳入2010年1月至2022年3月共34例接受TAE治疗的肝包膜下血肿患者。
- 病因包括肝肿瘤破裂12例、外伤12例、医源性并发症9例、自发性出血1例。
- 根据血管造影有无逆部门静脉血流将患者分为两组进行比较。
关键影像表现/征象
- 血管造影显示逆部门静脉血流者18例。
诊断标准与关键数值
- 技术成功率为94.1%,临床成功率为73.5%。
- 两组间技术成功率、临床成功率及TAE后血检结果差异均无统计学意义。
临床应用与阅片要点
- TAE可作为肝包膜下血肿的有效止血治疗选择。
- 血管造影发现逆部门静脉血流并非TAE失败或肝损伤加重的预测因素。
局限性
- 单中心回顾性研究,样本量34例,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: This study aimed to evaluate the technical and clinical success rates of transcatheter arterial embolization (TAE) for subcapsular hematoma of the liver.
METHODS: Between January 2010 and March 2022, 34 patients underwent TAE for subcapsular hematomas of the liver. The causes of subcapsular hematoma were liver tumor rupture (n = 12), trauma (n = 12), iatrogenic complications (n = 9), and spontaneous bleeding (n = 1). The technical and clinical success rates of TAE, blood test results after TAE and additional treatments were evaluated. The patients were divided into either with or without retrograde segmental or lobar portal venous flow on angiography. Technical and clinical success rates and blood test results after TAE were compared between the two groups.
RESULTS: Technical and clinical success rates were 94.1% and 73.5%, respectively. Six patients died within one month of TAE. A repeat TAE was performed in three patients. Surgical removal and hemostasis for subcapsular hematoma were done in four patients. One patient had liver failure. The retrograde portal venous flow was observed in 18 patients. The difference in technical and clinical success rates and blood test results after TAE between the two groups was statistically insignificant.
CONCLUSION: TAE is an effective and safe treatment for subcapsular hematomas of the liver. The success rates of TAE and liver damage due to TAE did not differ between patients with and without retrograde portal venous flow.
引用
- Onishi, Shimizu, Oka, et al. Transcatheter arterial embolization for subcapsular hematoma of the liver. Abdom Radiol (NY). 2022. PMID: 36378282. doi:10.1007/s00261-022-03732-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。